KR20150010240A - Injectable tissue volume replacement material comprising cartilage - Google Patents

Injectable tissue volume replacement material comprising cartilage Download PDF

Info

Publication number
KR20150010240A
KR20150010240A KR20130084960A KR20130084960A KR20150010240A KR 20150010240 A KR20150010240 A KR 20150010240A KR 20130084960 A KR20130084960 A KR 20130084960A KR 20130084960 A KR20130084960 A KR 20130084960A KR 20150010240 A KR20150010240 A KR 20150010240A
Authority
KR
South Korea
Prior art keywords
cartilage
replacement material
volume
present
volume replacement
Prior art date
Application number
KR20130084960A
Other languages
Korean (ko)
Inventor
류승호
Original Assignee
류승호
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 류승호 filed Critical 류승호
Priority to KR20130084960A priority Critical patent/KR20150010240A/en
Priority to PCT/KR2014/006478 priority patent/WO2015009071A1/en
Priority to CN201480049764.8A priority patent/CN105530967B/en
Publication of KR20150010240A publication Critical patent/KR20150010240A/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/3612—Cartilage, synovial fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A61L27/3843—Connective tissue
    • A61L27/3852—Cartilage, e.g. meniscus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/60—Materials for use in artificial skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/06—Flowable or injectable implant compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Vascular Medicine (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Materials For Medical Uses (AREA)

Abstract

The present invention relates to a bulk replacement material for injection transplantation, and more particularly, to a reconstructed volume replacement material containing a cartilage for skeletal tissue defect repair and skeletal tissue bulking as well as skin repair and cosmetic improvement of skin due to trauma, Lt; RTI ID = 0.0 > transplantation < / RTI > The cartilage-containing volume replacement material containing cartilage according to the present invention can be manufactured by a relatively simple treatment process, a simple procedure using a syringe can be applied, scars are scarcely left after the procedure, inconvenience, Less swelling and a shorter recovery period.

Description

Injectable tissue volume replacement material comprising cartilage < RTI ID = 0.0 >

The present invention relates to a body volume replacement material for injection implantation including a cartilage, and more particularly, to a method for repairing damage or increasing the volume of soft tissues such as restoration of skin tissue damage due to trauma or the like, And to cartilage-containing injectable transplantable body bulk replacements that can be applied for the repair of skeletal tissue defects and the enhancement of skeletal tissues.

Methods of increasing body volume using conventional injections have been used to increase the volume of soft tissues such as skin by using synthetic materials such as autologous adipose tissue, homogenous or heterogeneous collagen, PLGA (poly lactic coglycolic acid) particles and gore-tex Soft tissue augmentation methods have been used predominantly.

These methods can increase the volume of soft tissues when the soft tissues and skeletal tissues are simultaneously defected. However, there are limitations in restoring or increasing the volume of the skeletal tissues, and it is not permanent, .

In Korean Patent Laid-Open Nos. 10-2002-0084056 and 10-2004-0058818, chondroblasts, osteoblasts, and lipid precursor cells are collected and chitosan sponge powder having a solid sponge structure, polyethylene, polytetrafluoroethylene (PTFE) Particles, PLGA (poly lactic coglycolic acid), etc., as a support structure, and then injected. These methods can increase the amount of the graft material, but they can be cultured by culturing the cells The complication of culturing process, the cost of expensive treatment, the prolongation of the operation period, and the inconvenience of patients suffering from side effects due to foreign substances due to the use of support structures made of foreign substances, There was a problem accompanying it.

KR 10-2002-0084056 A KR 10-2004-0058818 A KR 10-2004-0048382 A

Disclosure of Invention Technical Problem [8] Accordingly, the present invention has been made keeping in mind the above problems occurring in the prior art, and it is an object of the present invention to provide a cartilage which is separated from a human body, And to provide a body bulk substitute for injection grafts containing cartilage, which is capable of recovering bone defects and enhancing volume.

DISCLOSURE OF THE INVENTION In order to solve the above problems, the inventor of the present invention has conducted intensive research and found that, as a result, the cartilage is pulverized to a predetermined size and then mixed with one or more kinds selected from physiological saline and body fluid, As a result, it was surprisingly found that the bulk substitution and the enhancing effect were maintained without side effects for a long period of time, thereby completing the present invention.

Prior to the present invention, it has been attempted to apply soft tissue such as adipose tissue as an injection, but no attempt has been made to apply the cartilage itself directly as an injection.

Therefore, according to the present invention, a simple procedure such as injecting a body-volume replacement material containing cartilage in a state of preserving the structure of the cartilage and the fibrous material of the cartilage as it is, does not show side effects such as scarring It has been shown for the first time that damage to soft tissue or skeletal defect can be effectively treated.

In a preferred embodiment, the present invention provides cartilage separated from the body, comprising cartilage comminuted to a size of 0.1 to 1.5 mm.

The cartilage is preferably softened.

The cartilage is preferably at least one selected from the group consisting of ear cartilage, septum cartilage, and rat cartilage.

The volume substitute also includes at least one selected from physiological saline and body fluids.

It is preferable that a mixing volume ratio of at least one selected from the cartilage, physiological saline, and body fluid is 3: 7 to 7: 3.

The cartilage-containing volume replacement material for cartography according to the present invention can be manufactured by a comparatively simple treatment process, and can be applied not only to soft tissue but also to restore and increase volume of skeletal tissue. Also, a simple procedure using a syringe can be applied There is little scar left after the procedure, the patient feels discomfort after the procedure, the swelling is small, and the recovery period is shortened.

Figure 1 shows cartilage separated from the body.
Fig. 2 shows a state in which cartilage is crushed.
Fig. 3 shows a state in which the pulverized cartilage is filled into a syringe.
Fig. 4 shows a state in which the cartilage mixed with the physiological saline is filled in the syringe.
FIG. 5 shows a photomicrograph of a transplanted cartilage cell one year after transplantation of a volume replacement material for injection injection of the present invention into a patient. The part dyed in purple represents living chondrocytes.

Hereinafter, the present invention will be described in detail.

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a bulk replacement material capable of being injected and injected for injection (hereinafter, referred to as 'injection implantation') for the recovery and volume enhancement of soft tissues and skeletal tissues of a human body, The present invention relates to a body-size substitute manufactured by a simple treatment process of extracted cartilage itself.

Since the body volume replacement material of the present invention can be injected into a region to be implanted by filling the syringe and injected by injection, unlike the conventional implantation method through incision, there is almost no scar It can be applied to the volume of the remaining body or skeletal replacement procedure.

According to the present invention, as a cartilage separated from a body, there is provided a bulk replacement material for injection implantation characterized by comprising cartilage ground to a size of 0.1 to 1.5 mm.

The term " body " refers to the body of a mammal, preferably a human body, and specifically refers to human soft tissue and skeletal tissue.

The term 'cartilage' includes not only the cartilage (autologous cartilage) of the patient himself / herself to be treated but also cartilage of the other, and may be selected from the group consisting of the ear cartilage, the septum cartilage and the rheumatoid cartilage, The donor cartilage may be determined depending on the patient's condition. Preferably, autologous bone is used.

The term 'isolated cartilage' refers to a cartilage already separated from the body by surgical operation, and does not mean cartilage attached to the body.

The cartilage should be milled to a size suitable for operation with a syringe, such as a cannula, and the size of the mill may vary depending on the needle size of the syringe used. The volume replacement material for injectable implants of the present invention is preferably injected using, for example, a cannula having a needle outer diameter of 1.8-2.5 mm of the syringe. If the needle diameter of the syringe is too small, It may be difficult to inject the substitute material, and if the needle diameter of the syringe is too large, the injection needle hole remaining in the body during the procedure may become large and the scar may remain, which is undesirable. When the bulky substitute of the present invention is injected using, for example, a cannula having a needle outer diameter of 1.8-2.5 mm of the needle of a syringe, the cartilage has a width, a length and a height of 0.1-1.5 mm, 1.0 mm in size. The grinding may be performed using a surgical knife, a cutter, or the like. The pulverization is preferably carried out along the texture of the cartilage so that the possible cartilage tissue is not damaged. When the size is less than 0.1 mm, various kinds of fiber structures may be broken down in the matrix quality of the cartilage tissue structure, and the cartilage cells in the cartilage lobule may be destroyed to receive the surrounding nutrients and oxygen, , And when it exceeds 1.5 m, there is a problem in transplanting into a patient with a syringe.

It is preferable that the cartilage undergoes a softening process before or after being crushed. The softening process may be performed by a conventional method using a medical cartilage softening device (e.g., mallet) or the like.

The pulverized cartilage is mixed with at least one selected from physiological saline and body fluids. Herein, the " body fluid " is a liquid substance obtained by separating from the body, and includes a liquid substance But are not limited to, serum, platelet rich plasma (PRP), and stromal vascular fraction (SVF), for example. The mixing ratio of the cartilage, the physiological saline solution and the body fluid may be adjusted in consideration of the needle size of the syringe used and the easiness of injection at the time of operation. For example, one kind selected from crushed cartilage: physiological saline and body fluids Is preferably in the range of 3: 7 to 7: 3, more preferably in the range of 4: 6 to 6: 4. When the content of cartilage is less than the above range, the amount of physiological saline or the like is relatively large, swelling at the time of injection is increased, and it is difficult to precisely confirm the volume replacement effect at the time of the procedure, Is more than the above range, there is a problem that it may be difficult to inject.

The body cavity substitute for injectable transplantation of the present invention thus prepared can be injected directly into a transplantation site through a syringe or the like.

Hereinafter, the present invention will be described in more detail with reference to specific examples.

[ Example ]

1. Body volume Alternative  Produce

Ear cartilage which can be easily obtained from the body was used as donor cartilage (Fig. 1). Since the cartilage tissue structure has various kinds of fiber structures in the matrix and the cartilage cells are contained in the cartilage lobe, the fibrous structure and cartilage cells are basically not damaged, and the contact area with the transplantation tissue is widened, The cartilage was first cut to length of 1 mm in the longitudinal direction. The soft tissue was slightly different depending on the type of donor cartilage, but the soft tissue was retained in the direction of preserving the elastic fibers and other fibers contained in the cartilage. (Fig. 2). Thereafter, the crushed cartilage was filled in a 1 cc syringe (Fig. 3), and physiological saline was mixed (Fig. 4), and the crushed cartilage: physiological saline weight ratio was 4: 6.

2. Skin transplantation

Using a 2-0 cannula (needle outer diameter: 2.0 mm) used for injecting fat, a hole of about 2 mm was made in a region to be injected using the tip of a syringe, A substitute was injected.

3. Follow-up after transplantation

When the nutrients are not diffused and supplied from the surrounding tissue to the injected cartilage, the cartilage cells die. However, as shown in FIG. 5, when the cartilage cells were treated using the volume replacement material of the present invention, the cartilage cells of the implanted cartilage were alive .

When the transplanted cartilage cells die, the cartilage tissue is absorbed by the surrounding tissues and the volume is turned off. As a result, the volume replacement effect decreases with time. As a result of the operation using the skin transplanting composition of the present invention, As shown in FIG. 5, even when the cartilage is stored as it is and the cartilage is piled up in several layers, nutrients can easily diffuse from the surrounding tissues. Therefore, even after one year from the injection, It was confirmed that no absorption or off phenomenon occurred.

Claims (5)

A cartilage separated from a body, comprising cartilage ground to a size of 0.1 to 1.5 mm, and at least one selected from physiological saline and body fluids. The volume replacement material for injection insert according to claim 1, wherein the cartilage is softened. The volume replacement material for an injection insert according to claim 1, wherein the cartilage is selected from the group consisting of ear cartilage, septum cartilage, and rat cartilage. 2. The bulk replacement material of claim 1, wherein the body fluid is selected from serum, platelet rich plasma (PRP) and adipose stem cell fraction (SVF). The volume replacement material for injection grafts according to claim 1, wherein the volume ratio of at least one selected from the ground cartilage: physiological saline and body fluid is 3: 7 to 7: 3.
KR20130084960A 2013-07-18 2013-07-18 Injectable tissue volume replacement material comprising cartilage KR20150010240A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
KR20130084960A KR20150010240A (en) 2013-07-18 2013-07-18 Injectable tissue volume replacement material comprising cartilage
PCT/KR2014/006478 WO2015009071A1 (en) 2013-07-18 2014-07-17 Body volume substitute comprising cartilage for grafting by injection, and dual needle-type syringe for injecting same
CN201480049764.8A CN105530967B (en) 2013-07-18 2014-07-17 Including the double-needle type syringe that the injection transplantation of cartilage replaces material with body volume and injected for it

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20130084960A KR20150010240A (en) 2013-07-18 2013-07-18 Injectable tissue volume replacement material comprising cartilage

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020160011749A Division KR101713475B1 (en) 2016-01-29 2016-01-29 Injectable tissue volume replacement material comprising cartilage

Publications (1)

Publication Number Publication Date
KR20150010240A true KR20150010240A (en) 2015-01-28

Family

ID=52482105

Family Applications (1)

Application Number Title Priority Date Filing Date
KR20130084960A KR20150010240A (en) 2013-07-18 2013-07-18 Injectable tissue volume replacement material comprising cartilage

Country Status (1)

Country Link
KR (1) KR20150010240A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10213296B2 (en) 2015-10-23 2019-02-26 Min Bo SHIM Graft including osseous tissue and cartilage tissue for augmentation rhinoplasty, and method of performing augmentation rhinoplasty using the graft
WO2020036465A1 (en) * 2018-08-16 2020-02-20 가톨릭대학교 산학협력단 Pharmaceutical composition for treating cartilage damage, comprising nasal septum chondrocytes

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10213296B2 (en) 2015-10-23 2019-02-26 Min Bo SHIM Graft including osseous tissue and cartilage tissue for augmentation rhinoplasty, and method of performing augmentation rhinoplasty using the graft
WO2020036465A1 (en) * 2018-08-16 2020-02-20 가톨릭대학교 산학협력단 Pharmaceutical composition for treating cartilage damage, comprising nasal septum chondrocytes

Similar Documents

Publication Publication Date Title
DK2307065T3 (en) COMPOSITIONS AND METHODS FOR TISSUE FILLING AND REGULATION
RU2363496C2 (en) Way of soft tissues volume increase
CN108478868B (en) Preparation method and application of injectable allogeneic adipose acellular matrix particles
EP2851096B1 (en) Composition for repairing cartilage tissue, method for producing same, and use thereof
CN104055795B (en) A kind of injectable implant and preparation method thereof
KR101121154B1 (en) A composition for transplant comprising adipose stem cells or adipocytes
WO2013106715A1 (en) Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation
CN105169486A (en) Neural restoration material combined with acellular nerve application
JP2019529015A (en) Dermal layer for transplantation with increased survival rate and method for producing the same
Özdemir et al. Biological augmentation strategies in rotator cuff repair
KR101926751B1 (en) Coated Thread For Dermal Filling And Its Coating Method
CN110237302A (en) A kind of preparation method of articular cartilage repair materials-autologous platelet rich plasma combination hyaluronic acid gel
CN102178981B (en) Method for preparing cartilage repairing scaffold material
KR20150010240A (en) Injectable tissue volume replacement material comprising cartilage
CN105530967B (en) Including the double-needle type syringe that the injection transplantation of cartilage replaces material with body volume and injected for it
KR101713475B1 (en) Injectable tissue volume replacement material comprising cartilage
CN110769865A (en) Method for producing and using collagen for cartilage tissue repair
KR100956267B1 (en) A semi-floating composition for transplant comprising elastin as a stabilizing agent
KR100539371B1 (en) In vitro cultured human preadipocyte for human soft tissue volume replacement with injectable material as a scaffold
KR20130131571A (en) Fat filler material and product using condensed single adipose cell(csac) and manufacturing method of it
Saridena et al. NanoMedicine; An Analysis of Hydrogels Scaffolds for Tissue Engineering Applications
KR20130016111A (en) Calcium alginate gel
EP4122441A1 (en) Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
E902 Notification of reason for refusal
A107 Divisional application of patent